Intestinal dysbiosis, gut hyperpermeability and bacterial translocation: Missing links between depression, obesity and type 2 diabetes?

Current Pharmaceutical Design

Volumn 22, Issue 40, 2016, Pages 6087-6106

  Slyepchenko, Anastasiya ^a,b   Maes, Michael ^c,d,e,f,g   Machado Vieira, Rodrigo ^h,i   Anderson, George ^j   Solmik, Marco ^k,l,m   Sanz, Yolanda ⁿ   Berk, Michael ^d,o   Köhlerp, Cristiano A ^p   Carvalhop, André F ^p  

^a MCMASTER UNIVERSITY   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

^c CHULALONGKORN UNIVERSITY   (Thailand)

^d DEAKIN UNIVERSITY   (Australia)

^e STATE UNIVERSITY OF LONDRINA   (Brazil)

^f MEDICAL UNIVERSITY OF PLOVDIV   (Bulgaria)

^g Revitalis   (Netherlands)

^h UNIVERSITY OF SÃO PAULO   (Brazil)

ⁱ NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

^j CRC Scotland and London   (United Kingdom)

^k UNIVERSITY OF PADOVA   (Italy)

^l Local Social Sanitary Unit   (Italy)

^m Institute for Clinical Research and Education in Medicine   (Italy)

ⁿ INSTITUTO DE AGROQUÍMICA Y TECNOLOGÍA DE ALIMENTOS CSIC   (Spain)

^o UNIVERSITY OF MELBOURNE   (Australia)

^p FEDERAL UNIVERSITY OF CEARÁ   (Brazil)

more..

Author keywords

Gut; Major depressive disorder; Metabolic syndrome; Microbiome; Obesity; Probiotics; Psychiatry; Type 2 diabetes mellitus

Indexed keywords

ADIPOCYTOKINE; ANTIOXIDANT; PROBIOTIC AGENT;

BACTERIAL TRANSLOCATION; BIBLIOGRAPHIC DATABASE; BODY MASS; CELLULAR IMMUNITY; CHRONIC FATIGUE SYNDROME; COMORBIDITY; DIABETIC PATIENT; DISEASE ASSOCIATION; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DYSBIOSIS; ENTEROENDOCRINE CELL; GLYCEMIC CONTROL; HUMAN; INFLAMMATION; INSULIN RESISTANCE; INTESTINE FLORA; MAJOR DEPRESSION; MENTAL PATIENT; METABOLIC SYNDROME X; MUCOSAL IMMUNITY; NEUROTOXICITY; NITROSATIVE STRESS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; OXIDATIVE STRESS; PATIENT COMPLIANCE; PHYSICAL INACTIVITY; PREVALENCE; PRIORITY JOURNAL; REVIEW; RISK FACTOR; ANIMAL; DEPRESSION; INTESTINE; METABOLISM; PERMEABILITY;

ANIMALS; BACTERIAL TRANSLOCATION; DEPRESSIVE DISORDER; DIABETES MELLITUS, TYPE 2; DYSBIOSIS; GASTROINTESTINAL MICROBIOME; HUMANS; INTESTINES; OBESITY; PERMEABILITY;

EID: 85007564412     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/1381612822666160922165706     Document Type: Review

References (329)

1. Wilson PW, D'Agostino RB, Sullivan L, Parise H, Kannel WB. Overweight and obesity as determinants of cardiovascular risk: the Framingham experience. Arch Intern Med 2002; 162: 1867-72.
2. Sheth SG, Gordon FD, Chopra S. Nonalcoholic steatohepatitis. Ann Intern Med 1997; 126: 137-45.
3. Simon GE, Von Korff M, Saunders K, et al. Association between obesity and psychiatric disorders in the US adult population. Arch Gen Psychiatry 2006; 63: 824-30.
4. Anderson RJ, Freedland KE, Clouse RE, Lustman PJ. The prevalence of comorbid depression in adults with diabetes a metaanalysis. Diabetes Care 2001; 24: 1069-78.
5. McEvoy JP, Meyer JM, Goff DC, et al. Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophr Res 2005; 80: 19-32.
6. Onyike CU, Crum RM, Lee HB, Lyketsos CG, Eaton WW. Is obesity associated with major depression? Results from the Third National Health and Nutrition Examination Survey. Am J Epidemiol 2003; 158: 1139-47.
7. Ali S, Stone M, Peters J, Davies M, Khunti K. The prevalence of co‐morbid depression in adults with Type 2 diabetes: a systematic review and meta‐analysis. Diabetic Med 2006; 23: 1165-73.
8. Dennis C-L, Ross LE, McIntyre RS, et al. Obesity in bipolar disorder and major depressive disorder: results from a national community health survey on mental health and well-being. Can J Psychiatry 2006; 51: 274-80.
9. Moussavi S, Chatterji S, Verdes E, Tandon A, Patel V, Ustun B. Depression, chronic diseases, and decrements in health: results from the World Health Surveys. Lancet 2007; 370: 851-8.
10. Sturm R. The effects of obesity, smoking, and drinking on medical problems and costs. Health Affairs 2002; 21: 245-53.
11. Görlitz N, Keller M, Ziegler A. Prevalence of complications and comorbidities in type 2 diabetes: a cross-sectional study of disease management program participants in Bavaria. Deutsche medizinische Wochenschrift (1946) 2008; 133: 1667-72.
12. Katon W, Ciechanowski P. Impact of major depression on chronic medical illness. J Psychosom Res 2002; 53: 859-63.
13. Dixon JB. The effect of obesity on health outcomes. Mol Cell Endocrinol 2010; 316: 104-8.
14. Association AD. Economic costs of diabetes in the US in 2007. Diabetes Care 2008; 31: 596-615.
15. Must A, Spadano J, Coakley EH, Field AE, Colditz G, Dietz WH. The disease burden associated with overweight and obesity. JAMA 1999; 282: 1523-9.
16. Von Korff M, Katon W, Lin EH, et al. Work disability among individuals with diabetes. Diabetes Care 2005; 28: 1326-32.
17. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 2002; 287: 356-9.
18. Dandona P, Aljada A, Bandyopadhyay A. Inflammation: the link between insulin resistance, obesity and diabetes. Trends Immunol 2004; 25: 4-7.
19. Miller AH, Maletic V, Raison CL. Inflammation and its discontents: the role of cytokines in the pathophysiology of major depression. Biol Psychiatry 2009; 65: 732-41.
20. Pickup JC. Inflammation and activated innate immunity in the pathogenesis of type 2 diabetes. Diabetes Care 2004; 27: 813-23.
21. Lowell BB, Shulman GI. Mitochondrial dysfunction and type 2 diabetes. Science 2005; 307: 384-7.
22. Bournat JC, Brown CW. Mitochondrial dysfunction in obesity. Curr Opin Endocrinol Diabetes Obes 2010; 17: 446-52.
23. Maes M, Ruckoanich P, Chang YS, Mahanonda N, Berk M. Multiple aberrations in shared inflammatory and oxidative & nitrosative stress (IO&NS) pathways explain the co-association of depression and cardiovascular disorder (CVD), and the increased risk for CVD and due mortality in depressed patients. Prog Neuro- Psychopharmacol Biol Psychiatry 2011; 35: 769-83.
24. Vargas HO, Nunes SOV, Barbosa DS, et al. Castelli risk indexes 1 and 2 are higher in major depression but other characteristics of the metabolic syndrome are not specific to mood disorders. Life Sci 2014; 102: 65-71.
25. Bortolasci CC, Vargas HO, Nunes SOV, et al. Factors influencing insulin resistance in relation to atherogenicity in mood disorders, the metabolic syndrome and tobacco use disorder. J Affect Disord 2015; 179: 148-55.
26. Kleinridders A, Cai W, Cappellucci L, et al. Insulin resistance in brain alters dopamine turnover and causes behavioral disorders. Proc Natl Acad Sci USA 2015; 112: 3463-8.
27. Black PH. The inflammatory response is an integral part of the stress response: Implications for atherosclerosis, insulin resistance, type II diabetes and metabolic syndrome X. Brain Behav Immun 2003; 17: 350-64.
28. Kan C, Silva N, Golden SH, et al. A systematic review and metaanalysis of the association between depression and insulin resistance. Diabetes Care 2013; 36: 480-9.
29. Holt RI, de Groot M, Golden SH. Diabetes and depression. Curr Diab Rep 2014; 14: 491.
30. Kan C, Pedersen NL, Christensen K, et al. Genetic overlap between type 2 diabetes and depression in Swedish and Danish twin registries. Mol Psychiatry 2016; 21(7): 903-9.
31. O'Neil A, Jacka FN, Quirk SE, et al. A shared framework for the common mental disorders and Non-Communicable Disease: key considerations for disease prevention and control. BMC Psychiatry 2015; 15: 15.
32. Maes M, Kubera M, Leunis J-C. The gut-brain barrier in major depression: intestinal mucosal dysfunction with an increased translocation of LPS from gram negative enterobacteria (leaky gut) plays a role in the inflammatory pathophysiology of depression. Neuroendocrinol Lett 2008; 29: 117-24.
33. Anderson G, Maes M. The gut–brain axis: The role of melatonin in linking psychiatric, inflammatory and neurodegenerative conditions. Adv Integr Med 2015; 2: 31-7.
34. Slyepchenko A, Carvalho FA, Cha SD, Kasper S, McIntyre SR. Gut emotions-mechanisms of action of probiotics as novel therapeutic targets for depression and anxiety disorders. CNS Neurol Disord-Drug Targets 2014; 13: 1770-86.
35. Tilg H, Kaser A. Gut microbiome, obesity, and metabolic dysfunction. J Clin Invest 2011; 121: 2126.
36. Sanz Y, Olivares M, Moya-Pérez Á, Agostoni C. Understanding the role of gut microbiome in metabolic disease risk. Pediatr Res 2014; 77: 236-44.
37. Sanz Y, Moya-Pérez A. Microbiota, inflammation and obesity. In: Lyte M, Cryon JF, eds. Microbial Endocrinology: The Microbiota- Gut-Brain Axis in Health and Disease. USA: Springer 2014; pp. 291-317.
38. Sanz Y, Rastmanesh R, Agostonic C. Understanding the role of gut microbes and probiotics in obesity: how far are we? Pharmacol Res 2013; 69: 144-55.
39. Scott KM, McGee MA, Wells JE, Browne MAO. Obesity and mental disorders in the adult general population. J Psychosom Res 2008; 64: 97-105.
40. Blaine B. Does depression cause obesity? A meta-analysis of longitudinal studies of depression and weight control. J Health Psychol 2008; 13: 1190-7.
41. Luppino FS, de Wit LM, Bouvy PF, et al. Overweight, obesity, and depression: a systematic review and meta-analysis of longitudinal studies. Arch Gen Psychiatry 2010; 67: 220-9.
42. Anderson SE, Cohen P, Naumova EN, Jacques PF, Must A. Adolescent obesity and risk for subsequent major depressive disorder and anxiety disorder: prospective evidence. Psychosom Med 2007; 69: 740-7.
43. Egede LE, Zheng D. Independent factors associated with major depressive disorder in a national sample of individuals with diabetes. Diabetes Care 2003; 26: 104-11.
44. Mezuk B, Eaton WW, Albrecht S, Golden SH. Depression and type 2 diabetes over the lifespan a meta-analysis. Diabetes Care 2008; 31: 2383-90.
45. Knol M, Twisk J, Beekman A, Heine R, Snoek F, Pouwer F. Depression as a risk factor for the onset of type 2 diabetes mellitus. A meta-analysis. Diabetologia 2006; 49: 837-45.
46. Everson SA, Maty SC, Lynch JW, Kaplan GA. Epidemiologic evidence for the relation between socioeconomic status and depression, obesity, and diabetes. J Psychosom Res 2002; 53: 891-5.
47. Vaiserman A. Epigenetic programming by early‐life stress: Evidence from human populations. Dev Dynamics 2015; 244: 254-65.
48. Bohacek J, Mansuy IM. Epigenetic inheritance of disease and disease risk. Neuropsychopharmacology 2013; 38: 220-236.
49. Lamers F, de Jonge P, Nolen WA, et al. Identifying depressive subtypes in a large cohort study: results from the Netherlands Study of Depression and Anxiety (NESDA). J Clin Psychiatry 2010; 71: 1582-9.
50. Cizza G, Ronsaville DS, Kleitz H, et al. Clinical subtypes of depression are associated with specific metabolic parameters and circadian endocrine profiles in women: the power study. PloS One 2012; 7: e28912.
51. Vogelzangs N, Beekman A, Boelhouwer IG, et al. Metabolic depression: a chronic depressive subtype? Findings from the InCHIANTI study of older persons. J Clin Psychiatry 2011; 72: 598-604.
52. Mansur RB, Brietzke E, McIntyre RS. Is there a “metabolic-mood syndrome”? A review of the relationship between obesity and mood disorders. Neurosci Biobehav Rev 2015; 52: 89-104.
53. Byers AL, Vittinghoff E, Lui LY, et al. Twenty-year depressive trajectories among older women. Arch Gen Psychiatry 2012; 69: 1073-9.
54. Vogelzangs N, Kritchevsky SB, Beekman AT, et al. Obesity and onset of significant depressive symptoms: Results from a community- based cohort of older men and women. J Clin Psychiatry 2010; 71: 391.
55. Ciechanowski PS, Katon WJ, Russo JE. Depression and diabetes: impact of depressive symptoms on adherence, function, and costs. Arch Intern Med 2000; 160: 3278-85.
56. Simon GE, Katon WJ, Lin EH, et al. Diabetes complications and depression as predictors of health service costs. Gen Hosp Psychiatry 2005; 27: 344-51.
57. Egede LE, Zheng D, Simpson K. Comorbid depression is associated with increased health care use and expenditures in individuals with diabetes. Diabetes Care 2002; 25: 464-70.
58. Gonzalez JS, Peyrot M, McCarl LA, et al. Depression and diabetes treatment nonadherence: a meta-analysis. Diabetes Care 2008; 31: 2398-2403.
59. Egede LE. Diabetes, major depression, and functional disability among US adults. Diabetes Care 2004; 27: 421-8.
60. Vamos EP, Mucsi I, Keszei A, Kopp MS, Novak M. Comorbid depression is associated with increased healthcare utilization and lost productivity in persons with diabetes: a large nationally representative Hungarian population survey. Psychosom Med 2009; 71: 501-7.
61. De Groot M, Anderson R, Freedland KE, Clouse RE, Lustman PJ. Association of depression and diabetes complications: a metaanalysis. Psychosom Med 2001; 63: 619-30.
62. Labad J, Price J, Strachan M, et al. Symptoms of depression but not anxiety are associated with central obesity and cardiovascular disease in people with type 2 diabetes: the Edinburgh Type 2 Diabetes Study. Diabetologia 2010; 53: 467-71.
63. Kimbro LB, Steers WN, Mangione CM, Duru OK, Ettner SL. The association of depression and the cardiovascular risk factors of blood pressure, HbA1c, and body mass index among patients with diabetes: results from the translating research into action for diabetes study. Int J Endocrinol 2012; 2012: 747460.
64. De la Roca-Chiapas JM, Hernandez-Gonzalez M, Candelario M, et al. Association between depression and higher glucose levels in middle-aged Mexican patients with diabetes. Rev Invest Clin 2013; 65: 209-13.
65. Lustman PJ, Anderson RJ, Freedland KE, et al. Depression and poor glycemic control: a meta-analytic review of the literature. Diabetes Care 2000; 23: 934-42.
66. Lasserre AM, Glaus J, Vandeleur CL, et al. Depression with atypical features and increase in obesity, body mass index, waist circumference, and fat mass: a prospective, population-based study. JAMA Psychiatry 2014; 71: 880-8.
67. Carpenter KM, Hasin DS, Allison DB, Faith MS. Relationships between obesity and DSM-IV major depressive disorder, suicide ideation, and suicide attempts: results from a general population study. Am J Public Health 2000; 90: 251.
68. Penninx BW, Beekman AT, Honig A, et al. Depression and cardiac mortality: results from a community-based longitudinal study. Arch Gen Psychiatry 2001; 58: 221-7.
69. Jiang J, Ahn J, Huang W-Y, Hayes RB. Association of obesity with cardiovascular disease mortality in the PLCO trial. Prevent Med 2013; 57: 60-4.
70. Kivimäki M, Hamer M, Batty GD, et al. Antidepressant Medication Use, Weight Gain, and Risk of Type 2 Diabetes A populationbased study. Diabetes Care 2010; 33: 2611-6.
71. Clark NG. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 2004; 27: 596.
72. Goodnick PJ, Henry JH, Buki V. Treatment of depression in patients with diabetes mellitus. J Clin Psychiatry 1995; 56(4): 128-36.
73. Trento M, Kucich C, Tibaldi P, et al. A study of central serotoninergic activity in healthy subjects and patients with Type 2 diabetes treated by traditional one-to-one care or Group Care. J Endocrinol Invest 2010; 33: 624-8.
74. Callaly E, Walder K, Morris G, Maes M, Debnath M, Berk M. Mitochondrial dysfunction in the pathophysiology of bipolar disorder: effects of pharmacotherapy. Mini Rev Med Chem 2015; 15: 355-65.
75. Kloiber S, Ising M, Reppermund S, et al. Overweight and obesity affect treatment response in major depression. Biol Psychiatry 2007; 62: 321-6.
76. Marcus MD, Wing RR, Guare J, Blair EH, Jawad A. Lifetime prevalence of major depression and its effect on treatment outcome in obese type II diabetic patients. Diabetes Care 1992; 15: 253-5.
77. Legenbauer T, Petrak F, de Zwaan M, Herpertz S. Influence of depressive and eating disorders on short-and long-term course of weight after surgical and nonsurgical weight loss treatment. Compr Psychiatry 2011; 52: 301-11.
78. Ohsiek S, Williams M. Psychological factors influencing weight loss maintenance: an integrative literature review. J Am Acad Nurse Pract 2011; 23: 592-601.
79. Simon GE, Rohde P, Ludman EJ, et al. Association between change in depression and change in weight among women enrolled in weight loss treatment. Gen Hospital Psychiatry 2010; 32: 583-9.
80. Busch AM, Whited MC, Appelhans BM, et al. Reliable change in depression during behavioral weight loss treatment among women with major depression. Obesity 2013; 21: E211-8.
81. Sullivan PF, Neale MC, Kendler KS. Genetic epidemiology of major depression: review and meta-analysis. Am J Psychiatry 2014.
82. Almgren P, Lehtovirta M, Isomaa B, et al. Heritability and familiality of type 2 diabetes and related quantitative traits in the Botnia Study. Diabetologia 2011; 54: 2811-9.
83. Poulsen P, Kyvik KO, Vaag A, Beck-Nielsen H. Heritability of type II (non-insulin-dependent) diabetes mellitus and abnormal glucose tolerance–a population-based twin study. Diabetologia 1999; 42: 139-45.
84. Bell CG, Walley AJ, Froguel P. The genetics of human obesity. Nat Rev Genet 2005; 6: 221-34.
85. Faith MS, Kral TV. Social Environmental and Genetic Influences on Obesity and Obesity-Promoting Behaviors: Fostering Research Integration. In: Hernandez LM, Blazer DG, Eds. Genes, behavior and the social environment: moving beyond the nature/nature debate. Washinghton (DC): National Academic Press 2006.
86. Rosmond R, Björntorp P, Occupational Status, Cortisol Secretory Pattern, and Visceral Obesity in Middle‐aged Men. Obesity Res 2000; 8: 445-50.
87. Williams LJ, Brennan SL, Henry MJ, et al. Area-based socioeconomic status and mood disorders: cross-sectional evidence from a cohort of randomly selected adult women. Maturitas 2011; 69: 173-8.
88. Mujica-Parodi L, Renelique R, Taylor M. Higher body fat percentage is associated with increased cortisol reactivity and impaired cognitive resilience in response to acute emotional stress. Int J Obesity 2009; 33: 157-65.
89. Jones A, McMillan MR, Jones RW, et al. Adiposity is associated with blunted cardiovascular, neuroendocrine and cognitive responses to acute mental stress. PloS One 2012; 7: e39143.
90. Brown ES, Varghese FP, McEwen BS. Association of depression with medical illness: does cortisol play a role? Biol Psychiatry 2004; 55: 1-9.
91. Stetler C, Miller GE. Depression and hypothalamic-pituitaryadrenal activation: a quantitative summary of four decades of research. Psychosom Med 2011; 73: 114-26.
92. Dowlati Y, Herrmann N, Swardfager W, et al. A meta-analysis of cytokines in major depression. Biol Psychiatry 2010; 67: 446-57.
93. Liu Y, Ho RC-M, Mak A. Interleukin (IL)-6, tumour necrosis factor alpha (TNF-α) and soluble interleukin-2 receptors (sIL-2R) are elevated in patients with major depressive disorder: a meta-analysis and meta-regression. J Affect Disord 2012; 139: 230-9.
94. Martin-Subero M, Anderson G, Kanchanatawan B, Berk M, Maes M. Comorbidity between depression and inflammatory bowel disease explained by immune-inflammatory, oxidative, and nitrosative stress; tryptophan catabolite; and gut–brain pathways. CNS Spectrums 2016; 21(2): 184-98.
95. Leonard B, Maes M. Mechanistic explanations how cell-mediated immune activation, inflammation and oxidative and nitrosative stress pathways and their sequels and concomitants play a role in the pathophysiology of unipolar depression. Neurosci Biobehav Rev 2012; 36 764-85.
96. Moylan S, Berk M, Dean OM, et al. Oxidative & nitrosative stress in depression: why so much stress? Neurosci Biobehav Rev 2014; 45: 46-62.
97. Anderson G, Maes M. Oxidative/nitrosative stress and immunoinflammatory pathways in depression: treatment implications. Curr Pharm Des 2014; 20: 3812-47.
98. Gałecki P, Talarowska M, Anderson G, Berk M, Maes M. Mechanisms underlying neurocognitive dysfunctions in recurrent major depression. Medical science monitor: Int Med J Exp Clin Res 2015; 21: 1535.
99. Howren MB, Lamkin DM, Suls J. Associations of depression with C-reactive protein, IL-1, and IL-6: a meta-analysis. Psychosom Med 2009; 71: 171-86.
100. Hannestad J, DellaGioia N, Bloch M. The effect of antidepressant medication treatment on serum levels of inflammatory cytokines: a meta-analysis. Neuropsychopharmacology 2011; 36: 2452-9.
101. Maes M, Meltzer HY, Bosmans E, et al. Increased plasma concentrations of interleukin-6, soluble interleukin-6, soluble interleukin-2 and transferrin receptor in major depression. J Affect Disord 1995; 34: 301-9.
102. Schmidt MI, Duncan BB, Sharrett AR, et al. Markers of inflammation and prediction of diabetes mellitus in adults (Atherosclerosis Risk in Communities study): a cohort study. Lancet 1999; 353: 1649-52.
103. Pickup JC, Chusney GD, Thomas SM, Burt D. Plasma interleukin- 6, tumour necrosis factor α and blood cytokine production in type 2 diabetes. Life Sci 2000; 67: 291-300.
104. Spranger J, Kroke A, Möhlig M, et al. Inflammatory cytokines and the risk to develop type 2 diabetes results of the prospective population- based eur prospective investigation into cancer and nutrition (EPIC)-potsdam study. Diabetes 2003; 52: 812-7.
105. Herder C, Brunner EJ, Rathmann W, et al. Elevated levels of the anti-inflammatory interleukin-1 receptor antagonist precede the onset of type 2 diabetes the whitehall II study. Diabetes Care 2009; 32: 421-3.
106. Pickup J, Mattock M, Chusney G, Burt D. NIDDM as a disease of the innate immune system: association of acute-phase reactants and interleukin-6 with metabolic syndrome X. Diabetologia 1997; 40: 1286-92.
107. Herder C, Illig T, Rathmann W, et al. Inflammation and type 2 diabetes: results from KORA Augsburg. Gesundheitswesen (Bundesverband der Arzte des Offentlichen Gesundheitsdienstes (Germany)) 2005; 67: S115-21.
108. Alvarez A, Faccioli J, Guinzbourg M, et al. Endocrine and inflammatory profiles in type 2 diabetic patients with and without major depressive disorder. BMC Res Notes 2013; 6: 61.
109. Lee C, Adler A, Sandhu M, et al. Association of C-reactive protein with type 2 diabetes: prospective analysis and meta-analysis. Diabetologia 2009; 52: 1040-7.
110. Sell H, Eckel J. Chemotactic cytokines, obesity and type 2 diabetes: in vivo and in vitro evidence for a possible causal correlation? Proc Nutr Soc 2009; 68: 378-84.
111. Choi J, Joseph L, Pilote L. Obesity and C‐reactive protein in various populations: a systematic review and meta‐analysis. Obesity Rev 2013; 14: 232-44.
112. Tsigos C, Kyrou I, Chala E, et al. Circulating tumor necrosis factor alpha concentrations are higher in abdominal versus peripheral obesity. Metabolism 1999; 48: 1332-5.
113. Hotamisligil GS, Arner P, Caro JF, Atkinson RL, Spiegelman BM. Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance. J Clin Invest 1995; 95: 2409.
114. Illán-Gómez F, Gonzálvez-Ortega M, Orea-Soler I, et al. Obesity and inflammation: change in adiponectin, C-reactive protein, tumour necrosis factor-alpha and interleukin-6 after bariatric surgery. Obesit Surg 2012; 22: 950-5.
115. Maes M, Anderson G, Kubera M, Berk M. Targeting classical IL-6 signalling or IL-6 trans-signalling in depression? Exp Opin Ther Targets 2014; 18: 495-512.
116. Maes M, Berk M, Goehler L, et al. Depression and sickness behavior are Janus-faced responses to shared inflammatory pathways. BMC Med 2012; 10: 66.
117. Quan N, Avitsur R, Stark JL, et al. Molecular mechanisms of glucocorticoid resistance in splenocytes of socially stressed male mice. J Neuroimmunol 2003; 137: 51-8.
118. Korn T, Bettelli E, Oukka M, Kuchroo VK. IL-17 and Th17 Cells. Annu Rev Immunol 2009; 27: 485-517.
119. Su DL, Lu ZM, Shen MN, Li X, Sun LY. Roles of pro-and antiinflammatory cytokines in the pathogenesis of SLE. BioMed Res Int 2012; 2012.
120. Slyepchenko A, Maes M, Kohler CA, et al. T helper 17 cells may drive neuroprogression in major depressive disorder: Proposal of an integrative model. Neurosci Biobehav Rev 2016; 64: 83-100.
121. Haapakoski R, Ebmeier KP, Alenius H, Kivimaki M. Innate and adaptive immunity in the development of depression: An update on current knowledge and technological advances. Prog Neuropsychopharmacol Biol Psychiatry 2016; 66: 63-72.
122. Winer S, Paltser G, Chan Y, et al. Obesity predisposes to Th17 bias. Eur J Immunol 2009; 39: 2629-35.
123. Bertola A, Ciucci T, Rousseau D, et al. Identification of adipose tissue dendritic cells correlated with obesity-associated insulinresistance and inducing Th17 responses in mice and patients. Diabetes 2012; 61: 2238-47.
124. DeFuria J, Belkina AC, Jagannathan-Bogdan M, et al. B cells promote inflammation in obesity and type 2 diabetes through regulation of T-cell function and an inflammatory cytokine profile. Proc Natl Acad Sci USA 2013; 110: 5133-8.
125. Moya-Pérez A, Neef A, Sanz Y. Bifidobacterium pseudocatenulatum CECT 7765 reduces obesity-associated inflammation by restoring the lymphocyte-macrophage balance and gut microbiota structure in high-fat diet-fed mice. PloS One 2015; 10: e0126976.
126. Monk JM, Hou TY, Turk HF, et al. Dietary n-3 polyunsaturated fatty acids (PUFA) decrease obesity-associated Th17 cell-mediated inflammation during colitis. PLoS One 2012; 7(11): e49739.
127. Łuczyński W, Grubczak K, Moniuszko M, Głowińska-Olszewska B, Bossowski A. Elevated levels of Th17 cells in children with central obesity. Scandinavian J Clin Lab Invest 2015; 75: 595-601.
128. Zúñiga LA, Shen WJ, Joyce-Shaikh B, et al. IL-17 regulates adipogenesis, glucose homeostasis, and obesity. J Immunol 2010; 185: 6947-59.
129. Hong M, Zheng J, Ding ZY, et al. Imbalance between Th17 and Treg cells may play an important role in the development of chronic unpredictable mild stress-induced depression in mice. Neuroimmunomodulation 2013; 20: 39-50.
130. Beurel E, Harrington LE, Jope RS. Inflammatory T helper 17 cells promote depression-like behavior in mice. Biol Psychiatry 2013; 73: 622-30.
131. Chen Y, Jiang T, Chen P, et al. Emerging tendency towards autoimmune process in major depressive patients: a novel insight from Th17 cells. Psychiatr Res 2011; 188: 224-30.
132. Olefsky JM, Glass CK. Macrophages, inflammation, and insulin resistance. Annu Rev Physiol 2010; 72: 219-46.
133. Nguyen KD, Qiu Y, Cui X, et al. Alternatively activated macrophages produce catecholamines to sustain adaptive thermogenesis. Nature 2011; 480: 104-8.
134. Nakagawa Y, Chiba K. Role of microglial m1/m2 polarization in relapse and remission of psychiatric disorders and diseases. Pharmaceuticals 2014; 7: 1028-48.
135. Carvalho AF, Rocha DQ, McIntyre RS, et al. Adipokines as emerging depression biomarkers: a systematic review and meta-analysis. J Psychiatr Res 2014; 59: 28-37.
136. Lago F, Dieguez C, Gómez-Reino J, Gualillo O. Adipokines as emerging mediators of immune response and inflammation. Nat Clin Pract Rheumatol 2007; 3: 716-24.
137. Lehto S, Huotari A, Niskanen L, et al. Serum adiponectin and resistin levels in major depressive disorder. Acta Psychiatr Scand 2010; 121: 209-15.
138. Pasco JA, Jacka FN, Williams LJ, et al. Leptin in depressed women: cross-sectional and longitudinal data from an epidemiologic study. J Affect Disord 2008; 107: 221-5.
139. Milaneschi Y, Sutin AR, Terracciano A, et al. The association between leptin and depressive symptoms is modulated by abdominal adiposity. Psychoneuroendocrinology 2014; 42: 1-10.
140. Pearson S, Schmidt M, Patton G, et al. Depression and Insulin Resistance Cross-sectional associations in young adults. Diabetes Care 2010; 33: 1128-33.
141. Weber-Hamann B, Hentschel F, et al. Hypercortisolemic depression is associated with increased intra-abdominal fat. Psychosomatic Med 2002; 64: 274-7.
142. McIntyre RS, Soczynska JK, Konarski JZ, Kennedy SH. The effect of antidepressants on glucose homeostasis and insulin sensitivity: synthesis and mechanisms. Expert Opin Drug Saf 2006; 5(1): 157-68.
143. Diener C, Kuehner C, Brusniak W, Ubl B, Wessa M, Flor H. A meta-analysis of neurofunctional imaging studies of emotion and cognition in major depression. Neuroimage 2012; 61: 677-85
144. Kullmann S, Heni M, Veit R, et al. The obese brain: association of body mass index and insulin sensitivity with resting state network functional connectivity. Hum Brain Mapping 2012; 33: 1052-61.
145. Garcia-Garcia I, Jurado M, Garolera M, et al. Functional connectivity in obesity during reward processing. Neuroimage 2013; 66: 232-9.
146. Cole J, Boyle C, Simmons A, et al. Body mass index, but not FTO genotype or major depressive disorder, influences brain structure. Neuroscience 2013; 252: 109-17.
147. Solinas M, Goldberg SR. Motivational effects of cannabinoids and opioids on food reinforcement depend on simultaneous activation of cannabinoid and opioid systems. Neuropsychopharmacology 2005; 30: 2035-45.
148. Kennedy SE, Koeppe RA, Young EA, Zubieta J-K. Dysregulation of endogenous opioid emotion regulation circuitry in major depression in women. Arch Gen Psychiatry 2006; 63: 1199-208.
149. Hamon M, Blier P. Monoamine neurocircuitry in depression and strategies for new treatments. Prog Neuro-Psychopharmacol Biol Psychiatry 2013; 45: 54-63.
150. Volkow ND, Wang G-J, Baler RD. Reward, dopamine and the control of food intake: implications for obesity. Trends Cogn Sci 2011; 15: 37-46.
151. Brown JM, Yamamoto BK. Effects of amphetamines on mitochondrial function: role of free radicals and oxidative stress. Pharmacol Ther 2003; 99: 45-53.
152. DeFronzo RA. Bromocriptine: a sympatholytic, D2-dopamine agonist for the treatment of type 2 diabetes. Diabetes Care 2011; 34: 789-94.
153. Haase J, Brown E. Integrating the monoamine, neurotrophin and cytokine hypotheses of depression—A central role for the serotonin transporter? Pharmacol Ther 2015; 147: 1-11.
154. Horáček J, Kuzmiaková M, Höschl C, Andĕl M, Bahbonh R. The relationship between central serotonergic activity and insulin sensitivity in healthy volunteers. Psychoneuroendocrinology 1999; 24: 785-97.
155. Isaac R, Boura-Halfon S, Gurevitch D, Shainskaya A, Levkovitz Y, Zick Y. Selective serotonin reuptake inhibitors (SSRIs) inhibit insulin secretion and action in pancreatic β cells. J Biol Chem 2013; 288: 5682-93.
156. Brunoni AR, Lopes M, Fregni F. A systematic review and metaanalysis of clinical studies on major depression and BDNF levels: implications for the role of neuroplasticity in depression. Int J Neuropsychopharmacology 2008; 11: 1169-80.
157. Stanek K, Gunstad J, Leahey T, et al. Serum brain-derived neurotrophic factor is associated with reduced appetite in healthy older adults. J Nutr Health Aging 2008; 12: 183-5.
158. Kernie SG, Liebl DJ, Parada LF. BDNF regulates eating behavior and locomotor activity in mice. EMBO J 2000; 19: 1290-300.
159. Geroldi D, Minoretti P, Emanuele E. Brain-derived neurotrophic factor and the metabolic syndrome: more than just a hypothesis. Med Hypotheses 2006; 67: 195-6.
160. Mou Z, Hyde TM, Lipska BK, et al. Human obesity associated with an intronic SNP in the brain-derived neurotrophic factor locus. Cell Rep 2015; 13: 1073-80.
161. Krabbe K, Nielsen A, Krogh-Madsen R, et al. Brain-derived neurotrophic factor (BDNF) and type 2 diabetes. Diabetologia 2007; 50: 431-8.
162. Fujinami A, Ohta K, Obayashi H, et al. Serum brain-derived neurotrophic factor in patients with type 2 diabetes mellitus: Relationship to glucose metabolism and biomarkers of insulin resistance. Clin Biochem 2008; 41: 812-7
163. Valko M, Leibfritz D, Moncol J, Cronin MT, Mazur M, Telser J. Free radicals and antioxidants in normal physiological functions and human disease. Int J Biochem Cell Biol 2007; 39: 44-84.
164. Maria Michel T, Pulschen D, Thome J. The role of oxidative stress in depressive disorders. Curr Pharm Des 2012; 18: 5890-9.
165. Halliwell B, Gutteridge JM. Free radicals in biology and medicine. Oxford: Oxford University Press 1999.
166. Niki E. Biomarkers of lipid peroxidation in clinical material. Biochim Biophys Acta (BBA)-Gen Subj 2014; 1840: 809-17.
167. Dalle-Donne I, Rossi R, Giustarini D, Milzani A, Colombo R. Protein carbonyl groups as biomarkers of oxidative stress. Clin Chim Acta 2003; 329: 23-38.
168. Maes M, Mihaylova I, Kubera M, Leunis JC, Geffard M. IgMmediated autoimmune responses directed against multiple neoepitopes in depression: new pathways that underpin the inflammatory and neuroprogressive pathophysiology. J Affect Disord 2011; 135: 414-8.
169. Swardfager W, Herrmann N, Mazereeuw G, Goldberger K, Harimoto T, Lanctôt KL. Zinc in depression: a meta-analysis. Biol Psychiatry 2013; 74: 872-8.
170. Maes M, Vandoolaeghe E, Neels H, et al. Lower serum zinc in major depression is a sensitive marker of treatment resistance and of the immune/inflammatory response in that illness. Biol Psychiatry 1997; 42: 349-58.
171. Cousins RJ, Leinart AS. Tissue-specific regulation of zinc metabolism and metallothionein genes by interleukin 1. The FASEB J 1988; 2: 2884-90.
172. Jacka FN, Maes M, Pasco JA, Williams LJ, Berk M. Nutrient intakes and the common mental disorders in women. J Affect Disord 2012; 141: 79-85.
173. Reunanen A, Knekt P, Marniemi J, Mäki J, Maatela J, Aromaa A. Serum calcium, magnesium, copper and zinc and risk of cardiovascular death. Eur J clinical nutrition 1996; 50: 431-7.
174. Nishikawa T, Edelstein D, Du XL, et al. Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature 2000; 404: 787-90.
175. Li J-M, Shah AM. ROS generation by nonphagocytic NADPH oxidase: potential relevance in diabetic nephropathy. J Am Soc Nephrol 2003; 14: S221-6.
176. Robertson RP, Harmon J, Tran PO, Tanaka Y, Takahashi H. Glucose toxicity in β-cells: type 2 diabetes, good radicals gone bad, and the glutathione connection. Diabetes 2003; 52: 581-7.
177. Hink U, Li H, Mollnau H, et al. Mechanisms underlying endothelial dysfunction in diabetes mellitus. Circulation Res 2001; 88:e14-e22.
178. VanderJagt DJ, Harrison JM, Ratliff DM, Hunsaker LA, Vander Jagt DL. Oxidative stress indices in IDDM subjects with and without long-term diabetic complications. Clin Biochem 2001; 34: 265-70.
179. 2 emission and cellular redox state link excess fat intake to insulin resistance in both rodents and humans. J Clin Invest 2009; 119: 573.
180. Rupérez AI, Gil A, Aguilera CM. Genetics of oxidative stress in obesity. Int J Mol Sci 2014; 15: 3118-44.
181. Furukawa S, Fujita T, Shimabukuro M, et al. Increased oxidative stress in obesity and its impact on metabolic syndrome. J Clin Invest 2004; 114: 1752.
182. Matsuzawa-Nagata N, Takamura T, Ando H, et al. Increased oxidative stress precedes the onset of high-fat diet–induced insulin resistance and obesity. Metabolism 2008; 57: 1071-7.
183. Black CN, Bot M, Scheffer PG, Cuijpers P, Penninx BW. Is depression associated with increased oxidative stress? A systematic review and meta-analysis. Psychoneuroendocrinology 2015; 51: 164-75.
184. Mazereeuw G, Herrmann N, Andreazza AC, Khan MM, Lanctôt KL. A meta-analysis of lipid peroxidation markers in major depression. Neuropsychiatr Dis Treat 2015; 11: 2479.
185. Liu T, Zhong S, Liao X, et al. A meta-analysis of oxidative stress markers in depression. PloS One 2015; 10: e0138904.
186. Beck-Friis J, Kjellman B, Aperia B, et al. Serum melatonin in relation to clinical variables in patients with major depressive disorder and a hypothesis of a low melatonin syndrome. Acta Psychiatr Scand 1985; 71: 319-30.
187. Maes F, Collignon A, Vandermeulen D, Marchal G, Suetens P. Multimodality image registration by maximization of mutual information. Med Imaging, IEEE Trans 1997; 16: 187-98.
188. Gawryluk JW, Wang JF, Andreazza AC, Shao L, Young LT. Decreased levels of glutathione, the major brain antioxidant, in postmortem prefrontal cortex from patients with psychiatric disorders. Int J Neuropsychopharmacol 2011; 14: 123-30.
189. Tsai M-C, Huang T-L. Increased activities of both superoxide dismutase and catalase were indicators of acute depressive episodes in patients with major depressive disorder. Psychiatry Res 2016; 235: 38-42.
190. Fernstrom JD. Role of precursor availability in control of monoamine biosynthesis in brain. Physiol Rev 1983; 63: 484-546.
191. Maes M, Leonard B, Myint A, Kubera M, Verkerk R. The new ‘5- HT’hypothesis of depression: cell-mediated immune activation induces indoleamine 2, 3-dioxygenase, which leads to lower plasma tryptophan and an increased synthesis of detrimental tryptophan catabolites (TRYCATs), both of which contribute to the onset of depression. Prog Neuro-Psychopharmacol Biol Psychiatry 2011; 35: 702-21.
192. Kim H, Chen L, Lim G, et al. Brain indoleamine 2, 3-dioxygenase contributes to the comorbidity of pain and depression. J Clin Invest 2012; 122: 2940.
193. Liebau C, Baltzer A, Schmidt S, et al. Interleukin-12 and interleukin- 18 induce indoleamine 2, 3-dioxygenase (IDO) activity in human osteosarcoma cell lines independently from interferon-gamma. Anticancer Res 2001; 22: 931-6.
194. Oxenkrug GF. Metabolic syndrome, age‐associated neuroendocrine disorders, and dysregulation of tryptophan—kynurenine metabolism. Ann N Y Acad Sci 2010; 1199: 1-14.
195. O'connor J, Lawson M, Andre C, et al. Lipopolysaccharide-induced depressive-like behavior is mediated by indoleamine 2, 3- dioxygenase activation in mice. Mol Psychiatry 2009; 14: 511-22.
196. Wölfler A, Abuja PM, Schauenstein K, Liebmann PM. Nacetylserotonin is a better extra-and intracellular antioxidant than melatonin. FEBS Lett 1999; 449: 206-10.
197. Anderson G, Kubera M, Duda W, Lasoń W, Berk M, Maes M. Increased IL-6 trans-signaling in depression: focus on the tryptophan catabolite pathway, melatonin and neuroprogression. Pharmacol Rep 2013; 65: 1647-54.
198. Kotler M, Rodríguez C, Sáinz RM, Antolin I, Menéndez‐Peláez A. Melatonin increases gene expression for antioxidant enzymes in rat brain cortex. J Pineal Res 1998; 24: 83-9.
199. Raison C, Borisov A, Woolwine B, Massung B, Vogt G, Miller A. Interferon-α effects on diurnal hypothalamic–pituitary–adrenal axis activity: relationship with proinflammatory cytokines and behavior. Mol Psychiatry 2010; 15: 535-47.
200. O'Connor JC, Lawson MA, André C, et al. Induction of IDO by bacille Calmette-Guerin is responsible for development of murine depressive-like behavior. J Immunol 2009; 182: 3202-12.
201. Godbout JP, Moreau M, Lestage J, et al. Aging exacerbates depressive- like behavior in mice in response to activation of the peripheral innate immune system. Neuropsychopharmacology 2008; 33: 2341-51.
202. Breum L, Rasmussen MH, Hilsted J, Fernstrom JD. Twenty-four– hour plasma tryptophan concentrations and ratios are below normal in obese subjects and are not normalized by substantial weight reduction. Am J Clin Nutr 2003; 77: 1112-8.
203. André C, Dinel A-L, Ferreira G, Layé S, Castanon N. Diet-induced obesity progressively alters cognition, anxiety-like behavior and lipopolysaccharide-induced depressive-like behavior: focus on brain indoleamine 2, 3-dioxygenase activation. Brain Behav Immun 2014; 41: 10-21.
204. Oxenkrug GF. Role of Kynurenine Pathway in Insulin Resistance: Toward Kynurenine Hypothesis of Insulin Resistance and Diabetes. In: Mittal S, Ed. Targeting the Broadly Pathogenic Kynurenine Pathway. USA: Springer 2015; pp. 169-78.
205. Sarkar SA, Wong R, Hackl SI, et al. Induction of indoleamine 2, 3- dioxygenase by interferon-γ in human islets. Diabetes 2007; 56: 72-9.
206. Brady KT, Sinha R. Co-occurring mental and substance use disorders: the neurobiological effects of chronic stress. Am J Psychiatry 2014.
207. Oliver G, Wardle J, Gibson EL. Stress and food choice: a laboratory study. Psychosom Med 2000; 62: 853-65.
208. Pervanidou P, Chrousos GP. Metabolic consequences of stress during childhood and adolescence. Metabolism 2012; 61: 611-9.
209. Tryon M, DeCant R, Laugero K. Having your cake and eating it too: a habit of comfort food may link chronic social stress exposure and acute stress-induced cortisol hyporesponsiveness. Physiol Behav 2013; 114: 32-7.
210. Marijnissen RM, Bus BA, Holewijn S, et al. Depressive symptom clusters are differentially associated with general and visceral obesity. J Am Geriatr Soc 2011; 59: 67-72.
211. Liu SC, Carvalho FA, McIntyre SR. Towards a “Metabolic” subtype of major depressive disorder: shared pathophysiological mechanisms may contribute to cognitive dysfunction. CNS Neurol Disord-Drug Targets 2014; 13: 1693-707.
212. McIntyre RS, Filteau M-J, Martin L, et al. Treatment-resistant depression: definitions, review of the evidence, and algorithmic approach. J Affect Disord 2014; 156: 1-7.
213. Kudlow P, Cha D, Lam R, McIntyre R. Sleep architecture variation: a mediator of metabolic disturbance in individuals with major depressive disorder. Sleep Med 2013; 14: 943-9.
214. Carabotti M, Scirocco A, Maselli MA, Severi C. The gut-brain axis: interactions between enteric microbiota, central and enteric nervous systems. Ann Gastroenterol 2015; 28: 203.
215. Lake JI, Heuckeroth RO. Enteric nervous system development: migration, differentiation, and disease. Am J Physiol- Gastrointestinal Liver Physiol 2013; 305: G1-G24.
216. Sam AH, Troke RC, Tan TM, Bewick GA. The role of the gut/brain axis in modulating food intake. Neuropharmacology 2012; 63: 46-56.
217. Murphy KG, Bloom SR. Gut hormones and the regulation of energy homeostasis. Nature 2006; 444: 854-9.
218. Porte Jr D, Baskin DG, Schwartz MW. Leptin and insulin action in the central nervous system. Nutr Rev 2002; 60: S20-9.
219. Jobst EE, Enriori PJ, Cowley MA. The electrophysiology of feeding circuits. Trends Endocrinol Metabol 2004; 15: 488-99.
220. Gunawardene AR, Corfe BM, Staton CA. Classification and functions of enteroendocrine cells of the lower gastrointestinal tract. Int J Exp Pathol 2011; 92: 219-31.
221. Furness JB, Rivera LR, Cho H-J, Bravo DM, Callaghan B. The gut as a sensory organ. Nat Rev Gastroenterol Hepatol 2013; 1010: 729-40.
222. Wang H, Steeds J, Motomura Y, et al. CD4+ T cell-mediated immunological control of enterochromaffin cell hyperplasia and 5- hydroxytryptamine production in enteric infection. Gut 2007; 56: 949-57.
223. Fukumoto S, Tatewaki M, Yamada T, et al. Short-chain fatty acids stimulate colonic transit via intraluminal 5-HT release in rats. Am J Physiol-Regulatory, Integrative Comparative Physiol 2003; 284: R1269-76.
224. Cummings DE, Overduin J. Gastrointestinal regulation of food intake. J Clin Invest 2007; 117: 13.
225. Chan H, Perrig A, Song D. Random key predistribution schemes for sensor networks. USA: SP’03 Proceeding of the 2003 IEEE Symposium on Security and Privacy 2003; pp. 197-213.
226. Faraj M, Havel PJ, Phélis S, Blank D, Sniderman AD, Cianflone K. Plasma acylation-stimulating protein, adiponectin, leptin, and ghrelin before and after weight loss induced by gastric bypass surgery in morbidly obese subjects. J Clin Endocrinol Metabol 2003; 88: 1594-602.
227. La Cava A, Matarese G. The weight of leptin in immunity. Nat Rev Immunol 2004; 4: 371-9.
228. Berg AH, Combs TP, Scherer PE. ACRP30/adiponectin: an adipokine regulating glucose and lipid metabolism. Trends Endocrinol Metabol 2002; 13: 84-9.
229. Weyer C, Funahashi T, Tanaka S, et al. Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metabol 2001; 86: 1930-5.
230. Fantuzzi G. Adiponectin and inflammation: consensus and controversy. J Allergy Clin Immunol 2008; 121: 326-30.
231. Cummings DE, Frayo RS, Marmonier C, Aubert R, Chapelot D. Plasma ghrelin levels and hunger scores in humans initiating meals voluntarily without time-and food-related cues. Am J Physiol- Endocrinol Metabol 2004; 287: E297-304.
232. Tong J, Prigeon RL, Davis HW, et al. Ghrelin suppresses glucosestimulated insulin secretion and deteriorates glucose tolerance in healthy humans. Diabetes 2010; 59: 2145-51.
233. Tschöp M, Smiley DL, Heiman ML. Ghrelin induces adiposity in rodents. Nature 2000; 407: 908-13.
234. Shiiya T, Nakazato M, Mizuta M, et al. Plasma ghrelin levels in lean and obese humans and the effect of glucose on ghrelin secretion. J Clin Endocrinol Metabol 2002; 87: 240-4.
235. Cummings DE, Weigle DS, Frayo RS, et al. Plasma ghrelin levels after diet-induced weight loss or gastric bypass surgery. New Eng J Med 2002; 346: 1623-30.
236. Mari A, Schmitz O, Gastaldelli A, et al. Meal and oral glucose tests for assessment of β-cell function: modeling analysis in normal subjects. Am J Physiol-Endocrinol Metabol 2002; 283: E1159-66.
237. Tang-Christensen M, Vrang N, Larsen PJ. Glucagon-like peptide 1 (7-36) amide's central inhibition of feeding and peripheral inhibition of drinking are abolished by neonatal monosodium glutamate treatment. Diabetes 1998; 47: 530-7.
238. Holst JJ, Gromada J. Role of incretin hormones in the regulation of insulin secretion in diabetic and nondiabetic humans. Am J Physiol-Endocrinol Metabol 2004; 287: E199-206.
239. Naslund E, Gryback P, Backman L, et al. Distal small bowel hormones (correlation with fasting antroduodenal motility and gastric emptying). Digest Dis Sci 1998; 43: 945-52.
240. Qin J, Li R, Raes J, et al. A human gut microbial gene catalogue established by metagenomic sequencing. Nature 2010; 464: 59-65.
241. Gueimonde M, Sakata S, Kalliomäki M, Isolauri E, Benno Y, Salminen S. Effect of maternal consumption of lactobacillus GG on transfer and establishment of fecal bifidobacterial microbiota in neonates. J Pediatr Gastroenterol Nutr 2006; 42: 166-70.
242. Vaishampayan PA, Kuehl JV, Froula JL, et al. Comparative metagenomics and population dynamics of the gut microbiota in mother and infant. Genome Biol Evol 2010; 2: 53-66.
243. Palmer C, Bik EM, DiGiulio DB, Relman DA, Brown PO. Development of the human infant intestinal microbiota. PLoS Biol 2007; 5: e177.
244. Stulberg E, Fravel D, Proctor LM, et al. An assessment of US microbiome research. Nat Microbiol 2016; 1: 15015.
245. Rakoff-Nahoum S, Paglino J, Eslami-Varzaneh F, Edberg S, Medzhitov R. Recogniion of commensal microflora by toll-like receptors is required for intestinal homeostasis. Cell 2004; 118: 229-41.
246. Turnbaugh PJ, Ley RE, Mahowald MA, Magrini V, Mardis ER, Gordon JI. An obesity-associated gut microbiome with increased capacity for energy harvest. Nature 2006; 444: 1027-131.
247. Clayton TA, Lindon JC, Cloarec O, et al. Pharmaco-metabonomic phenotyping and personalized drug treatment. Nature 2006; 440: 1073-7.
248. Benitez-Paez A, Portune K, Sanz Y. Species level resolution of 16S rRNA gene amplicons sequenced through MinIONTM portable nanopore sequencer. Gigascience 2016; 5: 4.
249. Yatsunenko T, Rey FE, Manary MJ, et al. Human gut microbiome viewed across age and geography. Nature 2012; 486: 222-7.
250. Barrett E, Ross R, O'Toole P, Fitzgerald G, Stanton C. γ‐Aminobutyric acid production by culturable bacteria from the human intestine. J Appl Microbiol 2012; 113: 411-7
251. Yano JM, Yu K, Donaldson GP, et al. Indigenous bacteria from the gut microbiota regulate host serotonin biosynthesis. Cell 2015; 161: 264-76.
252. Scheppach W. Effects of short chain fatty acids on gut morphology and function. Gut 1994; 35: S35-8.
253. Vrieze A, Van Nood E, Holleman F, et al. Transfer of intestinal microbiota from lean donors increases insulin sensitivity in individuals with metabolic syndrome. Gastroenterology 2012; 143: 913-16.
254. De Vadder F, Kovatcheva-Datchary P, Goncalves D, et al. Microbiota- generated metabolites promote metabolic benefits via gutbrain neural circuits. Cell 2014; 156: 84-96.
255. Reigstad CS, Salmonson CE, Rainey JF, et al. Gut microbes promote colonic serotonin production through an effect of short-chain fatty acids on enterochromaffin cells. FASEB J 2015; 29: 1395-403
256. Saint-Georges-Chaumet Y, Attaf D, Pelletier E, Edeas M. Targeting microbiota-mitochondria inter-talk: Microbiota control mitochondria metabolism. Cell Mol Biol (Noisy-le-grand) 2015; 61: 121-4.
257. Mayer EA, Padua D, Tillisch K. Altered brain‐gut axis in autism: Comorbidity or causative mechanisms? Bioessays 2014; 36: 933-9.
258. Song Y, Liu C, Finegold SM. Real-time PCR quantitation of clostridia in feces of autistic children. Appl Environ Microbiol 2004; 70: 6459-65.
259. Spiller R, Lam C. An update on post-infectious irritable bowel syndrome: role of genetics, immune activation, serotonin and altered microbiome. J Neurogastroenterol Motility 2012; 18: 258.
260. Crouzet L, Gaultier E, Del'Homme C, et al. The hypersensitivity to colonic distension of IBS patients can be transferred to rats through their fecal microbiota. Neurogastroenterol Motility 2013; 25: e272-82.
261. Sundin J, Rangel I, Fuentes S, et al. Altered faecal and mucosal microbial composition in post‐infectious irritable bowel syndrome patients correlates with mucosal lymphocyte phenotypes and psychological distress. Alim Pharmacol Ther 2015; 41: 342-51.
262. Ly NP, Litonjua A, Gold DR, Celedón JC. Gut microbiota, probiotics, and vitamin D: interrelated exposures influencing allergy, asthma, and obesity? J Allergy Clin Immunol 2011; 127: 1087-94.
263. Azad MB, Kozyrskyj AL. Perinatal programming of asthma: the role of gut microbiota. Clin Dev Immunol 2011; 2012: 93,2072.
264. Inagaki H, Suzuki T, Nomoto K, Yoshikai Y. Increased susceptibility to primary infection with Listeria monocytogenes in germfree mice may be due to lack of accumulation of L-selectin+ CD44+ T cells in sites of inflammation. Infect Immun 1996; 64: 3280-7.
265. Oliveira M, Tafuri W, Afonso L, et al. Germ-free mice produce high levels of interferon-gamma in response to infection with Leishmania major but fail to heal lesions. Parasitology 2005; 131: 477-88.
266. Honda K, Littman DR. The microbiome in infectious disease and inflammation. Annu Rev Immunol 2012; 30: 759.
267. Pabst O, Herbrand H, Friedrichsen M, et al. Adaptation of solitary intestinal lymphoid tissue in response to microbiota and chemokine receptor CCR7 signaling. J Immunol 2006; 177: 6824-32.
268. Ivanov II, de Llanos Frutos R, Manel N, et al. Specific microbiota direct the differentiation of IL-17-producing T-helper cells in the mucosa of the small intestine. Cell Host Microbe 2008; 4: 337-49.
269. Atarashi K, Tanoue T, Shima T, et al. Induction of colonic regulatory T cells by indigenous Clostridium species. Science 2011; 331: 337-41.
270. Geuking MB, Cahenzli J, Lawson MA, et al. Intestinal bacterial colonization induces mutualistic regulatory T cell responses. Immunity 2011; 34: 794-806.
271. Round JL, Lee SM, Li J, et al. The Toll-like receptor 2 pathway establishes colonization by a commensal of the human microbiota. Science 2011; 332: 974-7.
272. Chevalier C, Stojanović O, Colin DJ, et al. Gut microbiota orchestrates energy homeostasis during Cold. Cell 2015; 163: 1360-74.
273. De Palma G, Blennerhassett P, Lu J, et al. Microbiota and host determinants of behavioural phenotype in maternally separated mice. Nat Commun 2015; 6: 7735.
274. Petersson J, Schreiber O, Hansson GC, et al. Importance and regulation of the colonic mucus barrier in a mouse model of colitis. Am J Physiol-Gastrointestinal Liver Physiol 2011; 300: G327-33.
275. Fasano A. Leaky gut and autoimmune diseases. Clin Rev Allergy Immunol 2012; 42: 71-8.
276. Maes M, Kubera M, Leunis JC, Berk M. Increased IgA and IgM responses against gut commensals in chronic depression: further evidence for increased bacterial translocation or leaky gut. J Affect Disord 2012; 141: 55-62.
277. Lucas K, Maes M. Role of the Toll Like receptor (TLR) radical cycle in chronic inflammation: possible treatments targeting the TLR4 pathway. Mol Neurobiol 2013; 48: 190-204.
278. Takeda K, Akira S. TLR signaling pathways. Semin Immunol 2004; 16: 3-9.
279. Maes M, Kubera M, Leunis JC, Berk M, Geffard M, Bosmans E. In depression, bacterial translocation may drive inflammatory responses, oxidative and nitrosative stress (O&NS), and autoimmune responses directed against O&NS‐damaged neoepitopes. Acta Psychiatr Scand 2013; 127: 344-54.
280. Maes M, Ringel K, Kubera M, et al. In myalgic encephalomyelitis/ chronic fatigue syndrome, increased autoimmune activity against 5-HT is associated with immuno-inflammatory pathways and bacterial translocation. J Affect Disord 2013; 150: 223-30.
281. De Kort S, Keszthelyi D, Masclee A. Leaky gut and diabetes mellitus: what is the link? Obesity Rev 2011; 12: 449-58.
282. Cani PD, Neyrinck AM, Fava F, et al. Selective increases of bifidobacteria in gut microflora improve high-fat-diet-induced diabetes in mice through a mechanism associated with endotoxaemia. Diabetologia 2007; 50: 2374-83.
283. Cani PD, Bibiloni R, Knauf C, et al. Changes in gut microbiota control metabolic endotoxemia-induced inflammation in high-fat diet–induced obesity and diabetes in mice. Diabetes 2008; 57: 1470-81.
284. Cani PD, Delzenne NM. Gut microflora as a target for energy and metabolic homeostasis. Curr Opin Clin Nutr Metabol Care 2007; 10: 729-34.
285. Ley RE, Turnbaugh PJ, Klein S, Gordon JI. Microbial ecology: human gut microbes associated with obesity. Nature 2006; 444: 1022-3.
286. Turnbaugh PJ, Hamady M, Yatsunenko T, et al. A core gut microbiome in obese and lean twins. Nature 2009; 457: 480-4.
287. Le Chatelier E, Nielsen T, Qin J, et al. Richness of human gut microbiome correlates with metabolic markers. Nature 2013; 500: 541-6.
288. Larsen N, Vogensen FK, Van Den Berg F, et al. Gut microbiota in human adults with type 2 diabetes differs from non-diabetic adults. PloS One 2010; 5: e9085.
289. Zhang X, Shen D, Fang Z, et al. Human gut microbiota changes reveal the progression of glucose intolerance. PLoS One 2013; 8: e71108.
290. Yassour M, Lim MY, Yun HS, et al. Sub-clinical detection of gut microbial biomarkers of obesity and type 2 diabetes. Genome Med 2016; 8: 1.
291. Qin J, Li Y, Cai Z, et al. A metagenome-wide association study of gut microbiota in type 2 diabetes. Nature 2012; 490: 55-60.
292. Karlsson FH, Tremaroli V, Nookaew I, et al. Gut metagenome in Eur women with normal, impaired and diabetic glucose control. Nature 2013; 498: 99-103.
293. Forslund K, Hildebrand F, Nielsen T, et al. Disentangling type 2 diabetes and metformin treatment signatures in the human gut microbiota. Nature 2015; 528: 262-6.
294. Collins SM, Kassam Z, Bercik P. The adoptive transfer of behavioral phenotype via the intestinal microbiota: experimental evidence and clinical implications. Curr Opin Microbiol 2013; 16: 240-5.
295. Jašarević E, Howerton CL, Howard CD, Bale TL. Alterations in the vaginal microbiome by maternal stress are associated with meta bolic reprogramming of the offspring gut and brain. Endocrinol 2015; 156: 3265-76.
296. Naseribafrouei A, Hestad K, Avershina E, et al. Correlation between the human fecal microbiota and depression. Neurogastroenterol Motility 2014; 26: 1155-62.
297. Jiang H, Ling Z, Zhang Y, et al. Altered fecal microbiota composition in patients with major depressive disorder. Brain Behav Immun 2015; 48: 186-94.
298. Ridaura VK, Faith JJ, Rey FE, et al. Gut microbiota from twins discordant for obesity modulate metabolism in mice. Science 2013; 341: 1241214.
299. Cano PG, Santacruz A, Moya Á, Sanz Y. Bacteroides uniformis CECT 7771 ameliorates metabolic and immunological dysfunction in mice with high-fat-diet induced obesity. PloS one 2012; 7: e41079.
300. Liou AP, Paziuk M, Luevano JM, Machineni S, Turnbaugh PJ, Kaplan LM. Conserved shifts in the gut microbiota due to gastric bypass reduce host weight and adiposity. Sci Trans Med 2013; 5:178ra41-178ra41.
301. Bruce-Keller AJ, Salbaum JM, Luo M, et al. Obese-type gut microbiota induce neurobehavioral changes in the absence of obesity. Biol Psychiatry 2015; 77: 607-15.
302. Heijtz RD, Wang S, Anuar F, et al. Normal gut microbiota modulates brain development and behavior. Proc Natl Acad Sci USA 2011; 108: 3047-52.
303. Clarke G, Grenham S, Scully P, et al. The microbiome-gut-brain axis during early life regulates the hippocampal serotonergic system in a sex-dependent manner. Mol Psychiatry 2013; 18: 666-73.
304. Neufeld K, Kang N, Bienenstock J, Foster J. Reduced anxiety‐like behavior and central neurochemical change in germ‐free mice. Neurogastroenterol Motility 2011; 23: 255-e119.
305. Gareau MG, Wine E, Rodrigues DM, et al. Bacterial infection causes stress-induced memory dysfunction in mice. Gut 2011; 60(3): 307-17.
306. Bercik P, Denou E, Collins J, et al. The intestinal microbiota affect central levels of brain-derived neurotropic factor and behavior in mice. Gastroenterology 2011; 141: 599-609, 609.e1-3.
307. Sudo N, Chida Y, Aiba Y, et al. Postnatal microbial colonization programs the hypothalamic–pituitary–adrenal system for stress response in mice. J Physiol 2004; 558: 263-75.
308. Crumeyrolle-Arias M, Jaglin M, Bruneau A, et al. Absence of the gut microbiota enhances anxiety-like behavior and neuroendocrine response to acute stress in rats. Psychoneuroendocrinology 2014; 42: 207-17.
309. Maes M, Leunis JC. Normalization of leaky gut in chronic fatigue syndrome (CFS) is accompanied by a clinical improvement: effects of age, duration of illness and the translocation of LPS from gramnegative bacteria. Neuroendocrinol Lett 2008; 29: 902.
310. Ohland CL, Kish L, Bell H, et al. Effects of Lactobacillus helveticus on murine behavior are dependent on diet and genotype and correlate with alterations in the gut microbiome. Psychoneuroendocrinology 2013; 38: 1738-47.
311. Desbonnet L, Garrett L, Clarke G, Bienenstock J, Dinan TG. The probiotic Bifidobacteria infantis: an assessment of potential antidepressant properties in the rat. J Psychiatr Res 2008; 43: 164-74.
312. Messaoudi M, Violle N, Bisson JF, Desor D, Javelot H, Rougeot C. Beneficial psychological effects of a probiotic formulation (Lactobacillus helveticus R0052 and Bifidobacterium longum R0175) in healthy human volunteers. Gut Microbes 2011; 2: 256-61.
313. Bravo JA, Forsythe P, Chew MV, et al. Ingestion of Lactobacillus strain regulates emotional behavior and central GABA receptor expression in a mouse via the vagus nerve. Proc Natl Acad Sci USA: 2011; 108: 16050-5.
314. Savignac H, Tramullas M, Kiely B, Dinan T, Cryan J. Bifidobacteria modulate cognitive processes in an anxious mouse strain. Behav Brain Res 2015; 287: 59-72.
315. Perez-Burgos A, Wang B, Mao YK, et al. Psychoactive bacteria Lactobacillus rhamnosus (JB-1) elicits rapid frequency facilitation in vagal afferents. Am J Physiol-Gastrointestinal Liver Physiol 2013; 304: G211-20.
316. Sanz Y. Bifidobacteria in Foods: Health Effects. In: Caballero B, Finglas P, Toldrá F, Eds. The Encyclopedia of Food and Health. Oxford: Academic Press 2016; pp. 388-94.
317. Messaoudi M, Lalonde R, Violle N, et al. Assessment of psychotropic- like properties of a probiotic formulation (Lactobacillus helveticus R0052 and Bifidobacterium longum R0175) in rats and human subjects. Br J Nutr 2011; 105: 755-64.
318. Akkasheh G, Kashani-Poor Z, Tajabadi-Ebrahimi M, et al. Clinical and metabolic response to probiotic administration in patients with major depressive disorder: A randomized, double-blind, placebocontrolled trial. Nutrition 2016; 32(3): 315-20.
319. Rao AV, Bested AC, Beaulne TM, et al. A randomized, doubleblind, placebo-controlled pilot study of a probiotic in emotional symptoms of chronic fatigue syndrome. Gut Pathogens 2009; 1: 1-6.
320. Yang H, Zhao X, Tang S, et al. Probiotics reduce psychological stress in patients before laryngeal cancer surgery. Asia Pac J Clin Oncol 2016; 12(1): e92-6.
321. Steenbergen L, Sellaro R, van Hemert S, Bosch JA, Colzato LS. A randomized controlled trial to test the effect of multispecies probiotics on cognitive reactivity to sad mood. Brain, Behav Immun 2015.
322. Diop L, Guillou S, Durand H. Probiotic food supplement reduces stress-induced gastrointestinal symptoms in volunteers: a doubleblind, placebo-controlled, randomized trial. Nutr Res 2008; 28: 1-5.
323. Tillisch K, Labus J, Kilpatrick L, et al. Consumption of fermented milk product with probiotic modulates brain activity. Gastroenterology 2013; 144: 1394-1401. e4.
324. Mohammadi AA, Jazayeri S, Khosravi-Darani K, et al. The effects of probiotics on mental health and hypothalamic–pituitary–adrenal axis: A randomized, double-blind, placebo-controlled trial in petrochemical workers. Nutr Neurosci 2016; 19(9): 387-95.
325. Kadooka Y, Sato M, Imaizumi K, et al. Regulation of abdominal adiposity by probiotics (Lactobacillus gasseri SBT2055) in adults with obese tendencies in a randomized controlled trial. Eur J Clin Nutr 2010; 64: 636-43.
326. Asemi Z, Zare Z, Shakeri H, Sabihi SS, Esmaillzadeh A. Effect of multispecies probiotic supplements on metabolic profiles, hs-CRP, and oxidative stress in patients with type 2 diabetes. Ann Nutr Metabol 2013; 63: 1-9.
327. Ejtahed H, Mohtadi-Nia J, Homayouni-Rad A, et al. Effect of probiotic yogurt containing Lactobacillus acidophilus and Bifidobacterium lactis on lipid profile in individuals with type 2 diabetes mellitus. J Dairy Sci 2011; 94: 3288-94.
328. Lutgendorff F, Trulsson LM, van Minnen LP, et al. Probiotics enhance pancreatic glutathione biosynthesis and reduce oxidative stress in experimental acute pancreatitis. Am J Physiol- Gastrointestinal Liver Physiol 2008; 295: G1111-21.
329. Logan AC, Jacka FN, Prescott SL. Immune-microbiota interactions: Dysbiosis as a global health issue. Curr Allergy Asthma Rep 2016; 16: 13.